Medeon Biodesign, Inc. develops and markets medical device solutions in Taiwan. More Details
Flawless balance sheet and overvalued.
Share Price & News
How has Medeon Biodesign's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: 6499 is more volatile than 75% of TW stocks over the past 3 months, typically moving +/- 9% a week.
Volatility Over Time: 6499's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of TW stocks.
7 Day Return
TW Medical Equipment
1 Year Return
TW Medical Equipment
Return vs Industry: 6499 exceeded the TW Medical Equipment industry which returned 7% over the past year.
Return vs Market: 6499 underperformed the TW Market which returned 34.2% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is Medeon Biodesign's share price compared to the market and industry in the last 5 years?
Simply Wall St News
Is Medeon Biodesign undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate 6499's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate 6499's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: 6499 is unprofitable, so we can't compare its PE Ratio to the TW Medical Equipment industry average.
PE vs Market: 6499 is unprofitable, so we can't compare its PE Ratio to the TW market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate 6499's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: 6499 is good value based on its PB Ratio (1.1x) compared to the TW Medical Equipment industry average (2.1x).
How is Medeon Biodesign forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?
Forecasted Healthcare industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Medeon Biodesign has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
How has Medeon Biodesign performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: 6499 is currently unprofitable.
Growing Profit Margin: 6499 is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: 6499 is unprofitable, and losses have increased over the past 5 years at a rate of 10.7% per year.
Accelerating Growth: Unable to compare 6499's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 6499 is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (9.5%).
Return on Equity
High ROE: 6499 has a negative Return on Equity (-5.36%), as it is currently unprofitable.
How is Medeon Biodesign's financial position?
Financial Position Analysis
Short Term Liabilities: 6499's short term assets (NT$2.3B) exceed its short term liabilities (NT$137.1M).
Long Term Liabilities: 6499's short term assets (NT$2.3B) exceed its long term liabilities (NT$18.1M).
Debt to Equity History and Analysis
Debt Level: 6499 is debt free.
Reducing Debt: 6499 had no debt 5 years ago.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: 6499 has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: 6499 has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of 1.8% each year
What is Medeon Biodesign current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate 6499's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate 6499's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if 6499's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if 6499's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of 6499's dividend in 3 years as they are not forecast to pay a notable one for the TW market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Dr. Yue-Teh Jang, Ph D., serves as Chairman of the Board and Chief executive Officer at Medeon Biodesign, Inc. Dr. Jang had been General Manager at Medeon Biodesign, Inc. since December 22, 2012. Dr. Jang...
Experienced Management: 6499's management team is not considered experienced ( 0.7 years average tenure), which suggests a new team.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Medeon Biodesign, Inc.'s company bio, employee growth, exchange listings and data sources
- Name: Medeon Biodesign, Inc.
- Ticker: 6499
- Exchange: TPEX
- Founded: 2012
- Industry: Health Care Equipment
- Sector: Healthcare
- Market Cap: NT$5.029b
- Shares outstanding: 72.78m
- Website: https://www.medeonbio.com
Number of Employees
- Medeon Biodesign, Inc.
- 116, HouGang Street
- 7th Floor
Medeon Biodesign, Inc. develops and markets medical device solutions in Taiwan. It focuses on developing devices for minimally invasive surgeries, such as Duett, a vascular graft system; ClickClean, a solu...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/09/16 15:37|
|End of Day Share Price||2021/09/16 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.